Testing SARS-CoV-2 vaccine and therapeutics using human respiratory epithelium and organoid models
There is pressing urgency to develop vaccines and therapies to treat patients with COVID-19. This project will enable the production and utilisation of tissue-restricted stem-cell derived organoids to further our understanding of SARS-CoV-2 and the biological basis for infection. Using the natural cell host (human nasal epithelium) to test binding and vaccine-elicited neutralising antibodies will advance progress towards clinical trials. Similarly, using the nasal epithelial models will fast track the efficacy of COVID-19 therapeutics.
